Abstract
Long-term treatment with the typical antipsychotic drug, haloperidol, can lead to a sometimes irreversible motor disorder, tardive dyskinesia (TD). It has been hypothesized that increased release of glutamate due to prolonged neuroleptic drug treatment may result in an excitotoxic lesion in specific neuronal populations within the basal ganglia, leading to TD. We reported that treatment with haloperidol for 1 month results in an increase in the mean percentage of striatal asymmetric synapses containing a perforated postsynaptic density (PSD) and that these synapses are glutamatergic. Using quantitative immunocytochemistry, we found that depending on how long the animals had been off haloperidol following subchronic (30d) treatment, there was either a decrease (1 day off) or increase (3–4 days off) in the density of glutamate immunolabeling within the presynaptic terminals of synapses with perforated PSDs. Using a rat model for TD, animals in the current study were treated for 1 year with haloperidol and spontaneous oral dyskinesias (i.e. vacuous chewing movements, VCMs) were recorded. In these long-term treated animals we wanted to determine if there was a correlation between glutamate function, as measured by changes in synapses with perforated PSDs and the density of nerve terminal glutamate immunoreactivity, and VCM behavior. In drug treated rats which demonstrated either a high or low rate of VCMs, there was a significant increase in the mean percentage of asymmetric synapses in the dorsolateral striatum with perforated PSDs in both haloperidol-treated groups compared to vehicle-treated rats. There was a small but significant increase in the density of glutamate immunolabeling within striatal nerve terminals of the high VCM group compared to the low VCM group. There was, however, no difference in the density of glutamate immunolabeling between the high VCM group compared to the vehicle-treated animals. One reason for this lack of difference was partially due to a significant increase in nerve terminal area within the high VCM group compared to either the low VCM- or vehicle-treated groups. The larger nerve terminal size in the high VCM group may be due to a small but sustained increase in glutamate neurotransmitter release with the ability of the terminal to maintain its supply of glutamate, while the terminals in the low VCM group showed evidence of glutamate depletion. This finding would be consistent with the hypothesis that increased glutamatergic activity may be associated with TD.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Andreassen OA, Jørgensen HA (1994) GM1 ganglioside attentuates the development of vacuous chewing movements induced by long-term haloperidol treatment or rats. Psychopharmacology 116:517–522
Andreassen, OA, Finsen, BR, Østergasard K, West M, Jørgensen HA (1995) Association between haloperidol-induced oral movements and decreased number of enkephalin mRNA containing neurons in striatum of rats. Soc Neurosci Abstr 21:470
Benes FM, Paskevich PA, Davidson J, Domesick VB (1985) The effects of haloperidol on synaptic patterns in the rat striatum. Brain Res 329:265–274
Burt DR, Creese I, Snyder SH (1977) Antischizophrenic drugs: chronic treatment elevates dopamine receptors binding in brain. Science 196:326–328
Casey DE (1987) Tardive dyskinesia. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven Press, New York, pp 1411–1419
Casey DE (1989) Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 99:S47–53
Clow A, Jenner P, Marsden CD (1979) Changes in dopamine-mediated behavior during one year's neuroleptic administration. Eur J Pharmacol 57:365–375
De Keyser J (1991) Excitotoxic mechanisms may be involved in the pathophysiology of tardive dyskinesia. Clin Neuropharm 14:562–565
Eccles JC (1964) The physiology of synapses. Springer, New York
Egan MF, Hurd Y, Hyde TM, Weinberger TM, Wyatt RJ, Kleinman JE (1994) Alterations in mRNA levels of D2 receptors and neuropeptides in striatonigral and striatopallidal neurons of rats with neuroleptic-induced dyskinesia. Synapse 18:178–189
Einot I, Gabriel K (1975) A study of the powers of several members of multiple comparisons. J Am Statist Assoc 70:574–583
Farde F, Wiesel FA, Jansson P, Uppfeldt G, Wahlen A, Sedvall G (1988) An open label trial of raclopride in acute schizophrenia. Confirmation of D2-dopamine receptor occupancy by PET. Psychopharmacology 94:1–7
Favaron M, Manev H, Alho H, Bertolino M, Ferret B, Guidotti A, Costa E (1988) Gangliosides prevent glutamate and kainate neurotoxicity in primary neuronal cultures of neonatal rat cerebellum and cortex. Proc Natl Acad Sci USA 85:7351–7355
Geinisman Y, Morrel F, de Toledo-Morrell L (1991) Remodeling of synaptic architecture during hippocampal “kindling”. Proc Natl Acad Sci USA 85:3260–3264
Geinisman Y, de Toledo-Morrell L, Morrell F (1991) Induction of long-term potentiation is associated with an increase in the number of axospinous synapses with segmented postsynaptic densities. Brain Res 566:77–88
Greenough WT, West RW, De Voogd TJ (1978) Subsynaptic plate perforations: changes with age and experience in the rat. Science 202:1096–1098
Gunne LM, Andren PE (1993) An animal model for coexisting tardive dyskinesia and tardive parkinsonism: a glutamate hypothesis for tardive dyskinesia. Clin Neuropharmacol 16:90–95
Hepler JR, Toomim CS, McCarthy KD, Conti F, Battaglia G, Rustioni A, Petrusz P (1988) Characterization of antisera to glutamate and aspartate. J Histochem Cytochem 36:13–22
Heuser JE, Reese TS (1973) Structural changes after transmitter release at the frog neuromuscular junction. J Cell Biol 57:315–344
Hornykiewicz O (1973) Dopamine in the basal ganglia. Its role and therapeutic implications (including the clinical use ofL-DOPA). Br Med Bull 29:172–178
Jeste DV, Lohr JB, Manley M (1992) Study of neuropathological changes in striatum following 4, 8 or 12 months of treatment with fluphenazine in rats. Psychopharmacology 106:154–160
Jørgensen HA, Andreassen OA, Hole K (1994) Relationship between motor effects in rats following acute and chronic haloperidol treatment. Psychopharmacology 116:89–92
Kerkerian L, Dusticier N, Nieoullon A (1987) Modulatory effect of dopamine on high-affinity glutamate uptake in the rat striatum. J Neurochem 48:1301–1306
Kerns JM, Sierens DK, Kao LC, Klawans HL, Carvey PM (1992) Synaptic plasticity in the rat striatum following chronic haloperidol treatment. Clin Neuropharmacol 15:488–500
Lidsky TI, Schneider JS, Zuck LG, Yabolonsky-Alter E, Banerjee SP (1994) GM1 ganglioside attenuates changes in neurochemistry and behaviour caused by repeated haloperidol administration. Neurodegeneration 3:135–140
Manev H, Favaron M, Vicini S, Guidotti A, Costa E (1990) Glutamate-induced neuronal death in primary cultures of cerebellar granule cells: protection by synthetic derivatives of endogenous sphingolipids. J Pharmacol Exp Ther 252:419–427
McGeer EG, McGeer PL (1976) Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids. Nature 263:517–519
McGeorge AJ, Faull RLM (1989) The organization of the projection from the cerebral cortex to the striatum in the rat. Neuroscience 29:503–537
McMahon HT, Nicholls DG (1990) Glutamine and aspartate loading of synaptosomes: a reevaluation of effects on calcium-dependent excitatory amino acid release. J Neurochem 54:373–380
Meshul CK, Casey DE (1989) Regional, reversible ultrastructural changes in rat brain with chronic neuroleptic treatment. Brain Res 489:338–346
Meshul CK, Hopkins WF (1990) Presynaptic ultrastructural correlates of long-term potentiation in the CA1 subfield of the hippocampus. Brain Res 514:310–319
Meshul CK, Tan SE (1994) Haloperidol-induced morphological alterations are associated with changes in calcium/calmodulin kinase II activity and glutamate immunoreactivity. Synapse 18:205–217
Meshul CK, Janowsky A, Casey DE, Stallbaumer RK, Taylor B (1992) Effect of haloperidol and clozapine on the density of “perforated” synapses in caudate, nucleus accumbens, and medial prefrontal cortex. Psychopharmacology 106:45–52
Meshul CK, Stallbaumer RK, Taylor B, Janowsky A (1994) Haloperidol-induced morphological changes in striatrum are associated with glutamate synapses. Brain Res 648:181–195
Meshul CK, Buckman JF, Allen C, Riggan JP, Feller DJ (1996) Activation of corticostriatal pathway leads to similar morphological changes observed following haloperidol treatment. Synapse 22:350–369
Meshul CK, Stallbaumer RK, Allen C (1995) GM1 ganglioside administration partially counteracts the morphological changes associated with haloperidol treatment within the dorsal striatum of the rat. Psychopharmacology (in press)
Nielsen EB, Lyon M (1978) Evidence for cell loss in corpus striatum after long-term treatment with a neuroleptic drug (fluphenthixol) in rats. Psychopharmacology 59:85–89
Nieoullon A, Kerkerian L, Dusticier N (1983) Presynaptic dopaminergic control of high affinity glutamate uptake in the striatum. Neurosci Lett 43:191–196
Pakkenberg H, Fog R, Nilakantan B (1973) The long-term effect of perphenazine enanthate on the rat brain. Some metabolic and anatomical observations. Psychopharmacologia 29:329–336
Palmer AM, Hutson PH, Low SL, Bowen DM (1989) Extracellular concentrations of aspartate and glutamate in rat neostriatum following chemical stimulation of frontal cortex. Exp Brain Res 75:659–663
Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates, 2nd edn. Academic Press, San Diego
Phend KD, Weinberg RJ, Rustioni A (1992) Techniques to optimize post-embedding single and double staining for amino acid neurotransmitters. J Histochem Cytochem 40:1011–1020
Purves D, Hadley RD, Voyvodic JT (1986) Dynamic changes in the dendritic geometry of individual neurons visualized over periods of up to 3 months in the superior cervical ganglion of living mice. J Neurosci 6:1051–1060
Roberts RC, Gaither LA, Gao X-M, Kashyap SM, Tamminga CA (1995) Ultrastructural correlates of haloperidol-induced oral dyskinesias in rat striatum. Synapse 20:234–243
See RE, Chapman MA (1994) Chronic haloperidol, but not clozapine, produces altered oral movements and increased extracellular glutamate in rats. Eur J Pharmacol 263:269–276
See RE, Chapman MA, Meshul CK (1992) Comparison of chronic intermittent haloperidol and raclopride effects on striatal dopamine release and synaptic ultrastructure in rats. Synapse 12:147–154
Somogyi P, Halasy K, Somogyi J, Storm-Mathisen J, Ottersen OP (1986) Quantification of immunogold labelling reveals enrichment of glutamate in mossy and parallel fibre terminals in cat cerebellum. Neuroscience 19:1045–1050
Tarsy D, Baldessarini RJ (1974) Behavioural supersensitivity to apomorphine following chronic treatment with drugs which interfere with the synaptic function of catecholamines. Neuropharmacology 13:927–940
Uranova NA, Orlovskaya DD, Apel K, Klintsova AJ, Haselhorst U, Schenk H (1991) Morphometric study of synaptic patterns in the rat caudate nucleus and hippocampus under haloperidol treatment. Synapse 7:253–259
Waddington JL (1990) Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: phenomenology, pathophysiology and putative relationship to tardive dyskinesia. Psychopharmacology 101:431–447
Yamamoto BK, Cooperman MA (1994) Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J Neurosci 14:4159–4166
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Meshul, C.K., Allen, C., Andreassen, O.A. et al. Correlation of vacuous chewing movements with morphological changes in rats following 1-year treatment with haloperidol. Psychopharmacology 125, 238–247 (1996). https://doi.org/10.1007/BF02247334
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02247334